Gilead Expands Hep C Portfolio With LG Life Sciences Deal
This article was originally published in PharmAsia News
Executive Summary
Gilead Sciences is gaining a Phase II pan-caspase inhibitor for hepatitis C through a licensing agreement with LG Life Sciences worth up to $202 million announced Nov. 7
You may also be interested in...
LG Life Science Tops R&D Investment List of Korea-Listed Pharmas
SEOUL - Of the 37 local Korean pharmas listed on Korea's main KOSPI stock market, LG Life Science topped local pharmas in R&D investment last year in both scale and in proportion to its sales, according to a report released by a lawmaker in an Oct. 6 National Assembly session
LG Life Science Tops R&D Investment List of Korea-Listed Pharmas
SEOUL - Of the 37 local Korean pharmas listed on Korea's main KOSPI stock market, LG Life Science topped local pharmas in R&D investment last year in both scale and in proportion to its sales, according to a report released by a lawmaker in an Oct. 6 National Assembly session
Korean LG Life Sciences Plans BLA Submission For Biosimilar Somatropin To U.S. FDA
SEOUL - South Korea's LG Life Sciences completed its Phase III clinical trial of its slow-release recombinant human growth hormone somatropin weekly injection for treating adults with growth hormone deficiency, and is getting its biologics license application ready for U.S. FDA for the new formulation